Phase II Trial of Palbociclib in Patients With Metastatic Urothelial Cancer After Failure of First-Line Chemotherapy
Status:
Terminated
Trial end date:
2017-09-28
Target enrollment:
Participant gender:
Summary
This multicenter phase II trial will evaluate palbociclib (PD-0332991) in patients with
metastatic urothelial carcinoma (UC) with cyclin-dependent kinase inhibitor 2A (CDKN2A) (also
referred to as p16) loss and positive Retinoblastoma (Rb) expression after failure of
first-line chemotherapy.